Liu et al. (29) found that the mutation frequency of TET2 was 21% in 228 newly diagnosed Chinese MDS patients and 15% in 184 treated MDS patients by Next-Generation Sequencing (NGS), with a significantly higher mutation frequency in patients over 60 years old. This evidence concerns the gene TET2 and myelodysplastic syndrome.